<p>肯尼迪资本管理公司在最近向证券交易委员会（SEC）提交的 13F 文件中披露，其在 Scholar Rock Holding Corporation（NASDAQ:SRRK - 免费报告）中的持股在第二季度增加了 596.4%。该机构投资者在此期间额外购买了 46,722 股后，持有该公司 54,556 股股票。到最近一个季度末，肯尼迪资本管理公司大约拥有 Scholar Rock 0.06% 的股份，价值 1,932,000 美元。</p>
<ul>
<li>3 只被低估的股票在本财报季有反弹潜力</li>
</ul>
<p>其他机构投资者最近也调整了对该公司的持股。英维斯科有限公司在第二季度将其在 Scholar Rock 的持股增加了 12.8%。英维斯科有限公司目前拥有 61,964 股该公司的股票，价值 2,195,000 美元，此前在此期间又购买了 7,027 股。施罗德投资管理集团在第二季度将其在 Scholar Rock 的持股增加了 217.1%。施罗德投资管理集团目前拥有 191,998 股该公司的股票，价值 6,801,000 美元，此前在上个季度又购买了 131,458 股。挪威银行在第二季度购买了价值约 41,628,000 美元的 Scholar Rock 新头寸。Elevation Point Wealth Partners LLC 在第二季度获得了约 94,000 美元的 Scholar Rock 新头寸。最后，Inceptionr LLC 在第二季度购买了价值约 205,000 美元的 Scholar Rock 新股份。目前，91.08% 的股票由机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>几位研究分析师对该股票发表了评论。派珀·桑德勒在 9 月 24 日的研究报告中将 Scholar Rock 的目标价格从 52.00 美元下调至 51.00 美元，并对该公司给予 “增持” 评级。美国银行在 10 月 9 日的研究报告中开始覆盖 Scholar Rock。他们对该股票给予 “买入” 评级，目标价格为 53.00 美元。杰富瑞金融集团在 8 月 21 日的研究报告中开始覆盖 Scholar Rock。他们对该公司设定了 “买入” 评级和 50.00 美元的目标价格。Leerink Partners 在 9 月 15 日的研究报告中将 Scholar Rock 的评级提升至 “强力买入”。最后，Leerink Partners 在 9 月 15 日的研究报告中开始覆盖 Scholar Rock。他们对该公司设定了 “跑赢大盘” 评级和 51.00 美元的目标价格。四位分析师对该股票给予 “强力买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价格为 48.33 美元。</p>
<p><strong>查看我们对 SRRK 的最新股票分析</strong></p>
<h2>Scholar Rock 内部活动</h2>
<p>在相关消息中，董事 Katie Peng 在 9 月 16 日的交易中出售了 1,006 股 Scholar Rock 股票。该股票以平均价格 32.53 美元出售，总交易额为 32,725.18 美元。出售后，该董事直接持有 33,914 股公司股票，价值 1,103,222.42 美元。此交易代表其持股减少了 2.88%。该交易已在证券交易委员会的文件中披露，具体信息可通过此链接查看。此外，董事 Srinivas Akkaraju 在 10 月 3 日的交易中购买了 387,414 股该公司的股票。该股票以每股平均价格 37.27 美元收购，总价值为 14,438,919.78 美元。交易完成后，该董事持有 387,414 股公司股票，价值约 14,438,919.78 美元。此交易代表其持股增加了∞。有关此次购买的更多细节可在官方 SEC 披露中找到。内部人士在上个季度共出售了 143,999 股公司股票，价值 6,411,535 美元。内部人士持有 13.30% 的股票。</p>
<h2>Scholar Rock 股价下跌 0.4%</h2>
<p>NASDAQ SRRK 周一开盘价为 45.02 美元。该公司的市值为 45.9 亿美元，市盈率为-14.29，贝塔值为 0.60。Scholar Rock Holding Corporation 的 12 个月低点为 22.71 美元，12 个月高点为 46.98 美元。该公司的速动比率为 6.30，流动比率为 6.30，债务股本比率为 0.41。该公司的 50 日移动平均线为 35.09 美元，200 日移动平均线为 34.51 美元。</p>
<p>Scholar Rock（NASDAQ:SRRK - 获取免费报告）最近在 11 月 14 日发布了其财报。该公司报告本季度每股收益（EPS）为-0.90 美元，低于市场共识预期的-0.88 美元，差距为 0.02 美元。在去年同期，该公司每股收益为-0.66 美元。整体来看，卖方分析师预计 Scholar Rock Holding Corporation 在当前财年将发布-2.42 美元的每股收益。</p>
<h2>Scholar Rock 公司简介</h2>
<p>（免费报告）</p>
<p>Scholar Rock Holding Corporation 是一家生物制药公司，专注于发现、开发和交付用于治疗严重疾病的药物，这些疾病中蛋白质生长因子的信号传导起着基础性作用。该公司开发了 Apitegromab，这是一种抑制肌肉生长因子激活的药物，目前正在进行针对脊髓性肌萎缩症的第三阶段临床试验；以及 SRK-181，该药物已完成针对对检查点抑制剂疗法（如抗 PD-1 或抗 PD-L1 抗体疗法）耐药癌症的第一阶段临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Scholar Rock</li>
<li>卖空 - 利弊分析</li>
<li>Rubrik 的巨大反弹：为什么下一轮上涨可能会很快</li>
<li>能源和石油股票解析</li>
<li>Five Below 和 Dollar Tree 的财报信号显示消费者转变</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JSSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JSSw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Scholar Rock 吗？</h2>
<p>在考虑投资 Scholar Rock 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Scholar Rock 并不在名单上。</p>
<p>虽然 Scholar Rock 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SRRK

<p>肯尼迪资本管理公司在第二季度将其在 Scholar Rock Holding Corporation 的持股增加了 596.4%，目前持有 54,556 股，价值 193 万美元。其他机构投资者也调整了他们的持股。分析师对该股票给予了 “买入” 评级，平均目标价格为 48.33 美元。还报告了内部交易活动，包括股票的买卖。Scholar Rock 的股票开盘价为 45.02 美元，市值为 45.9 亿美元</p>

<p>Kennedy Capital Management LLC raised its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 596.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,556 shares of the company's stock after acquiring an additional 46,722 shares during the period. Kennedy Capital Management LLC owned approximately 0.06% of Scholar Rock worth $1,932,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>肯尼迪资本管理公司在最近向证券交易委员会（SEC）提交的 13F 文件中披露，其在 Scholar Rock Holding Corporation（NASDAQ:SRRK - 免费报告）中的持股在第二季度增加了 596.4%。该机构投资者在此期间额外购买了 46,722 股后，持有该公司 54,556 股股票。到最近一个季度末，肯尼迪资本管理公司大约拥有 Scholar Rock 0.06% 的股份，价值 1,932,000 美元。</p>
</div><ul>
<li>3 Beaten-Down Stocks With Rebound Potential This Earnings Season</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的股票在本财报季有反弹潜力</li>
</ul>
</div><p>Other institutional investors have also recently modified their holdings of the company. Invesco Ltd. increased its position in shares of Scholar Rock by 12.8% in the second quarter. Invesco Ltd. now owns 61,964 shares of the company's stock worth $2,195,000 after purchasing an additional 7,027 shares during the period. Schroder Investment Management Group grew its stake in Scholar Rock by 217.1% during the second quarter. Schroder Investment Management Group now owns 191,998 shares of the company's stock worth $6,801,000 after buying an additional 131,458 shares in the last quarter. Norges Bank bought a new position in Scholar Rock in the 2nd quarter valued at about $41,628,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Scholar Rock in the 2nd quarter valued at approximately $94,000. Finally, Inceptionr LLC bought a new stake in shares of Scholar Rock during the 2nd quarter worth approximately $205,000. 91.08% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者最近也调整了对该公司的持股。英维斯科有限公司在第二季度将其在 Scholar Rock 的持股增加了 12.8%。英维斯科有限公司目前拥有 61,964 股该公司的股票，价值 2,195,000 美元，此前在此期间又购买了 7,027 股。施罗德投资管理集团在第二季度将其在 Scholar Rock 的持股增加了 217.1%。施罗德投资管理集团目前拥有 191,998 股该公司的股票，价值 6,801,000 美元，此前在上个季度又购买了 131,458 股。挪威银行在第二季度购买了价值约 41,628,000 美元的 Scholar Rock 新头寸。Elevation Point Wealth Partners LLC 在第二季度获得了约 94,000 美元的 Scholar Rock 新头寸。最后，Inceptionr LLC 在第二季度购买了价值约 205,000 美元的 Scholar Rock 新股份。目前，91.08% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research analysts have commented on the stock. Piper Sandler lowered their price objective on shares of Scholar Rock from $52.00 to $51.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, September 24th. Bank of America began coverage on Scholar Rock in a research note on Thursday, October 9th. They issued a &#34;buy&#34; rating and a $53.00 price target on the stock. Jefferies Financial Group started coverage on Scholar Rock in a research report on Thursday, August 21st. They set a &#34;buy&#34; rating and a $50.00 price objective for the company. Leerink Partnrs raised Scholar Rock to a &#34;strong-buy&#34; rating in a research note on Monday, September 15th. Finally, Leerink Partners began coverage on Scholar Rock in a research note on Monday, September 15th. They set an &#34;outperform&#34; rating and a $51.00 target price for the company. Four analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $48.33.</p>
<div class="lb-trans"><p>几位研究分析师对该股票发表了评论。派珀·桑德勒在 9 月 24 日的研究报告中将 Scholar Rock 的目标价格从 52.00 美元下调至 51.00 美元，并对该公司给予 “增持” 评级。美国银行在 10 月 9 日的研究报告中开始覆盖 Scholar Rock。他们对该股票给予 “买入” 评级，目标价格为 53.00 美元。杰富瑞金融集团在 8 月 21 日的研究报告中开始覆盖 Scholar Rock。他们对该公司设定了 “买入” 评级和 50.00 美元的目标价格。Leerink Partners 在 9 月 15 日的研究报告中将 Scholar Rock 的评级提升至 “强力买入”。最后，Leerink Partners 在 9 月 15 日的研究报告中开始覆盖 Scholar Rock。他们对该公司设定了 “跑赢大盘” 评级和 51.00 美元的目标价格。四位分析师对该股票给予 “强力买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价格为 48.33 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on SRRK</strong></p>
<div class="lb-trans"><p><strong>查看我们对 SRRK 的最新股票分析</strong></p>
</div><h2>Insider Activity at Scholar Rock</h2>
<div class="lb-trans"><h2>Scholar Rock 内部活动</h2>
</div><p>In related news, Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $32.53, for a total transaction of $32,725.18. Following the sale, the director directly owned 33,914 shares in the company, valued at $1,103,222.42. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director Srinivas Akkaraju purchased 387,414 shares of the firm's stock in a transaction on Friday, October 3rd. The stock was acquired at an average price of $37.27 per share, with a total value of $14,438,919.78. Following the completion of the transaction, the director owned 387,414 shares in the company, valued at approximately $14,438,919.78. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 143,999 shares of company stock worth $6,411,535 in the last quarter. 13.30% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Katie Peng 在 9 月 16 日的交易中出售了 1,006 股 Scholar Rock 股票。该股票以平均价格 32.53 美元出售，总交易额为 32,725.18 美元。出售后，该董事直接持有 33,914 股公司股票，价值 1,103,222.42 美元。此交易代表其持股减少了 2.88%。该交易已在证券交易委员会的文件中披露，具体信息可通过此链接查看。此外，董事 Srinivas Akkaraju 在 10 月 3 日的交易中购买了 387,414 股该公司的股票。该股票以每股平均价格 37.27 美元收购，总价值为 14,438,919.78 美元。交易完成后，该董事持有 387,414 股公司股票，价值约 14,438,919.78 美元。此交易代表其持股增加了∞。有关此次购买的更多细节可在官方 SEC 披露中找到。内部人士在上个季度共出售了 143,999 股公司股票，价值 6,411,535 美元。内部人士持有 13.30% 的股票。</p>
</div><h2>Scholar Rock Trading Down 0.4%</h2>
<div class="lb-trans"><h2>Scholar Rock 股价下跌 0.4%</h2>
</div><p>NASDAQ SRRK opened at $45.02 on Monday. The company has a market cap of $4.59 billion, a price-to-earnings ratio of -14.29 and a beta of 0.60. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $46.98. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The business's fifty day moving average is $35.09 and its 200 day moving average is $34.51.</p>
<div class="lb-trans"><p>NASDAQ SRRK 周一开盘价为 45.02 美元。该公司的市值为 45.9 亿美元，市盈率为-14.29，贝塔值为 0.60。Scholar Rock Holding Corporation 的 12 个月低点为 22.71 美元，12 个月高点为 46.98 美元。该公司的速动比率为 6.30，流动比率为 6.30，债务股本比率为 0.41。该公司的 50 日移动平均线为 35.09 美元，200 日移动平均线为 34.51 美元。</p>
</div><p>Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the previous year, the company posted ($0.66) earnings per share. As a group, sell-side analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Scholar Rock（NASDAQ:SRRK - 获取免费报告）最近在 11 月 14 日发布了其财报。该公司报告本季度每股收益（EPS）为-0.90 美元，低于市场共识预期的-0.88 美元，差距为 0.02 美元。在去年同期，该公司每股收益为-0.66 美元。整体来看，卖方分析师预计 Scholar Rock Holding Corporation 在当前财年将发布-2.42 美元的每股收益。</p>
</div><h2>Scholar Rock Profile</h2>
<div class="lb-trans"><h2>Scholar Rock 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.</p>
<div class="lb-trans"><p>Scholar Rock Holding Corporation 是一家生物制药公司，专注于发现、开发和交付用于治疗严重疾病的药物，这些疾病中蛋白质生长因子的信号传导起着基础性作用。该公司开发了 Apitegromab，这是一种抑制肌肉生长因子激活的药物，目前正在进行针对脊髓性肌萎缩症的第三阶段临床试验；以及 SRK-181，该药物已完成针对对检查点抑制剂疗法（如抗 PD-1 或抗 PD-L1 抗体疗法）耐药癌症的第一阶段临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Scholar Rock</li>
<li>Short Selling - The Pros and Cons</li>
<li>Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast</li>
<li>Energy and Oil Stocks Explained</li>
<li>Five Below and Dollar Tree Earnings Signal a Shopper Shift</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Scholar Rock</li>
<li>卖空 - 利弊分析</li>
<li>Rubrik 的巨大反弹：为什么下一轮上涨可能会很快</li>
<li>能源和石油股票解析</li>
<li>Five Below 和 Dollar Tree 的财报信号显示消费者转变</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JSSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SRRK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Scholar Rock Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Scholar Rock 吗？</h2>
</div><p>Before you consider Scholar Rock, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Scholar Rock 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scholar Rock wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Scholar Rock 并不在名单上。</p>
</div><p>While Scholar Rock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Scholar Rock 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kennedy Capital Management LLC 在 Scholar Rock Holding Corporation $SRRK 中持有价值 193 万美元的头寸